Artificial intelligence in Genetic Testing of Inherited Disorders

Published on March 23, 2017

Image for Artificial intelligence in Genetic Testing of Inherited Disorders

Clinical interpretation of genetic data is a complex process, which involves connecting patient’s genetic variants and phenotypes with experimental scientific information. Blueprint Genetics is applying Artificial Intelligence (AI) in clinical interpretation to automate manually laborious interpretation processes and empower geneticists and clinicians to interpret patients’ test data accurately and consistently.

In this podcast, Massimiliano Gentile, Informatics Director, Ph.D. and Samuel Myllykangas, CTO, Ph.D, are discussing artificial intelligence in genetic testing of inherited disorders.

Key learning objectives:

  • Why AI is instrumental in advancing the interpretation of genetic testing data
  • How AI is applied for genetic testing of inherited disorders
  • What AI solutions Blueprint Genetics is offering for patients today and in the future to maximise the clinical impact and actionability from genetic testing of inherited disorders.

Array

Episode guests

Samuel Myllykangas

Samuel Myllykangas

Samuel is the Head of R&D and Operations at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his post-doctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor in patents of DNA sequencing methods.

Massimiliano Gentile

Massimiliano Gentile

Massimiliano has been at Blueprint Genetics from the onset, holding the position as Informatics Director and being responsible for the IT and bioinformatic activities of the company. He has vast experience in bioinformatics, especially in analysis of biological data from high throughput laboratory technologies, as well as in development of software and analysis pipelines. Upon completion of his PhD studies in cancer genetics at the University of Linköping, Sweden, he pursued post-doctoral studies in functional genomics at the University of Helsinki, Finland. He then joined the Bioinformatics Unit at the medical research institute Biomedicum Helsinki, analysing and developing methods for data analysis of data from microarray and next generation sequencing technologies. Before going Blueprint Genetics in March of 2012, Massimiliano spent 3 years developing software for analysis of data from high throughput applications at the Centre for Scientific Computing in Finland.

What do you want to hear next?